Pub. Date : 2019 Jun
PMID : 30976989
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Crizotinib, an oral small-molecule tyrosine kinase inhibitor (TKI) that targets anaplastic lymphoma kinase (ALK), MET, and ROS1, has shown marked antitumor activity in patients with ROS1-positive advanced NSCLC. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 2 | Crizotinib, an oral small-molecule tyrosine kinase inhibitor (TKI) that targets anaplastic lymphoma kinase (ALK), MET, and ROS1, has shown marked antitumor activity in patients with ROS1-positive advanced NSCLC. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 3 | OBJECTIVE: Our objective was to analyze the efficacy and safety of crizotinib treatment in Chinese patients with advanced NSCLC with ROS1 rearrangement in real-world clinical practice. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 4 | CONCLUSION: Crizotinib was effective and well tolerated in Chinese patients with ROS1-positive advanced NSCLC in real-world clinical practice. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |